← Back to headlines
ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer
ImmunityBio's stock surged following the EU's approval of ANKTIVA for bladder cancer treatment.
18 Feb, 22:37 — 18 Feb, 22:37
Sources
Showing 1 of 1 sources
Related Stories
Cornerstone Funds Declare Monthly Dividends and Announce 2026/2027 Distributions
3h ago
The OLB Group Reports Q2 Financials; FinVolution Group to Announce Results
5h ago
Mark Cuban and Tech Founders Oppose California Wealth Tax Proposal
7h ago
Greece to Save €2 Billion by Early Debt Repayment in 2026
8h ago